United Kingdom

People: Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

25 Jun 2019
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Behar, Greg 

Mr. Greg Behar is Independent Director of the Company. He joined our board of directors in November 2016 in connection with the equity investment in Aimmune by Nestle Health Science US Holdings, Inc. Mr. Behar currently serves as President and Chief Executive Officer of Nestlé Health Science S.A., a wholly-owned subsidiary of Nestlé S.A. (“Nestlé”), a nutrition, health and wellness company, which he joined in July 2014. Previously, Mr. Behar was President and Chief Executive Officer of Boehringer lngelheim Pharmaceuticals Inc. (USA), a pharmaceutical company, from 2011 to June 2014 and Corporate Vice President Region NECAR (North European Union, Canada and Australasia) for BoehringerIngelheim GmbH, a pharmaceutical company, from 2010 to 2011. He also spent seven years in marketing and sales leadership in various roles at Novartis AG, a healthcare company, following earlier work at Nestlé. Mr. Behar also serves on the boards of Seres Therapeutics, Inc., a microbiome therapeutics platform company, Accera, Inc., a clinical development company, Axcella Health, Inc., an amino acids therapeutics company, and Nestlé Health Science S.A. Mr. Behar is Chairman of the Board of Nutrition Science Partners and a member of the Steering Committee of Nestlé Institute of Health Sciences. Mr. Behar received a B.S. in Mechanical Engineering from the University of California, Los Angeles, an M.S. in Mechanical Engineering from EPFL in Switzerland and an M.B.A. from INSEAD in France. We believe that Mr. Behar is qualified to serve on our Board due to his extensive global management and leadership experience in the life science industry.

Basic Compensation

Total Annual Compensation, USD 236,789
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 236,789

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --